Induction therapy with basiliximab and full HLA mismatch.

Area of Science:

• Nephrology
• Immunology
• Transplantation

Background:

• Induction therapy is crucial for reducing rejection in high-risk transplant patients.
• Antithymocyte globulins are often preferred over basiliximab due to efficacy, despite higher risks.
• Basiliximab's safety in specific low-risk, high-mismatch populations requires further evaluation.

Purpose of the Study:

• To assess graft function and acute rejection in kidney transplant recipients with full HLA mismatches receiving basiliximab induction.
• To evaluate the safety of basiliximab in patients lacking other immunological risk factors.

Main Methods:

• Retrospective analysis of kidney transplant patients over a 4-year period.
• Comparison between patients with full HLA mismatches and those with 5 or fewer mismatches.
• Exclusion of patients with additional immunological risk factors.

Main Results:

• No significant differences in demographic features, cold ischemia times, or panel reactive antibodies between groups.
• Graft function at 12 and 24 months post-transplant was comparable between groups.
• Incidence of acute rejection episodes did not differ significantly between the studied groups.

Conclusions:

• Basiliximab induction therapy is a safe option for kidney transplant recipients with full HLA mismatches and no other immunological risk factors.
• The study supports the use of basiliximab in this specific patient cohort, demonstrating acceptable graft function and rejection rates.